Fikriye handan Kalkan

Dr. Fikriye handan Kalkan


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in The Eurasian Journal of Medicine
Verified
Journal Article
Open access
FKFikriye handan Kalkan
Fikriye handan Kalkan
EUElif Yılmazel Ucar
Elif Yılmazel Ucar
KKKamuran Kalkan
Kamuran Kalkan
OAOmer Araz
Omer Araz
Objective: Pulmonary hypertension (PH) is a common complication of chronic obstructive pulmonary disease (COPD) associated with a decrease in the survival rate of patients with COPD. Our aim was to investigate whether PH impairs the functional capacity and symptoms in patients with COPD. In addition, we aimed to evaluate the correlation between the functional capacity and symptoms score in patients with COPD. Materials and Methods: This prospective cross-sectional study enrolled 64 patients with moderate to severe COPD, prospectively. All patients underwent the pulmonary function test, echocardiography, 6-minute walk test (6MWT), and cardiopulmonary exercise testing (CPET). We applied the modified Medical Research Council (mMRC) dyspnea scale and COPD Assessment Test (CAT) to all patients. The mean pulmonary arterial pressure (mPAP) >30 mmHg with echocardiography was considered as PH. The patients were grouped according to the presence of PH as COPD-PH (n=30) and COPD-nonPH (n=34). Results: Hospitalization rate was higher in the COPD-PH group than in the COPD-nonPH group (p=0.006). The 6MWT results were lower in the COPD-PH group compared to the COPD-nonPH group (325±61 m vs. 354±46 m, respectively, p=0.025). In the COPD-PH group, the maximum oxygen consumption (VO2max) was lower, but the difference did not reach statistical significance (p=0.118). Although the maximum load and minute ventilation were lower in the COPD-PH group, the end-tidal pressure of CO2 (PETCO2) was higher (p=0.033, p=0.036, and p=0.009, respectively). However, the CAT score and mMRC were similar between the groups (p=0.405 and p=0.238, respectively). Conclusion: An elevated PAP in patients with COPD limits the exercise capacity. Using CPET in the functional evaluation of patients with COPD may be beneficial in the early detection of PH. Cite this article as: Kalkan F, Yılmazel Ucar E, Kalkan K, Araz O. Comparison of Functional Capacity and Symptoms of COPD Patients with and without Pulmonary Hypertension. Eurasian J Med 2020; 52(2): 166-70.

23 October 2025 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MDMakbule seda bayrak durmaz
Makbule seda bayrak durmaz
BÖBetül Özdel Öztürk
Betül Özdel Öztürk
BABegum Gorgulu Akin
Begum Gorgulu Akin
FKFikriye handan Kalkan
Fikriye handan Kalkan
ŞSŞadan Soyyiğit
Şadan Soyyiğit
Background: Autoimmune thyroid diseases (AITDs) are among the most frequently reported autoimmune manifestations in individuals with inborn errors of immunity (IEIs). While immune dysregulation in IEI is known to predispose patients to autoimmunity, data regarding the prevalence and characteristics of AITD in this population remain limited. This study aimed to assess the frequency of AITD and describe its clinical, serological, ultrasonographic, and immunological features in a cohort of adult IEI patients. Methods: This retrospective study included 45 adult IEI patients, excluding those with selective IgA deficiency. Demographic, clinical, and immunological data were collected from medical records. AITD diagnosis was based on thyroid-specific autoantibodies, thyroid function tests, and/or ultrasonographic features consistent with thyroiditis. Comparative analyses were conducted between patients with and without AITD. Results: AITD was identified in 7 patients (15.5%), including 6 with Hashimoto’s thyroiditis (HT) and 1 with seronegative chronic autoimmune thyroiditis (SN-CAT); no cases of Graves’ disease were observed. The majority of patients with AITD were female (85.7%), while only one case occurred in a male (14.3%). No statistically significant sex-based difference in AITD frequency was detected ( p = 0.225). Anti-thyroid peroxidase antibodies were positive in 85.7% of AITD patients, and anti-thyroglobulin antibodies in 60.0%. All were euthyroid at evaluation, though 57.1% were receiving L-thyroxine therapy. Non-AITD thyroid abnormalities were present in 12 patients (26.6%), including isolated serology and a solitary thyroid nodule. Compared with non-AITD patients, those with AITD exhibited significantly higher CD16⁺56⁺ NK cell percentages ( p = 0.010), while other lymphocyte subsets did not differ. No significant differences were observed regarding sex, IEI phenotype, non-thyroidal autoimmunity, or infection-related complications. Conclusions: In this adult IEI cohort, HT was the most prevalent autoimmune thyroid condition. Distinct immunological features, particularly increased NK cell frequencies, may reflect underlying immune dysregulation. These findings support systematic thyroid evaluation, even in asymptomatic IEI patients, and emphasize the need for larger, genetically diverse cohorts to validate and expand these observations.

5 November 2024 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
FKFikriye handan Kalkan
Fikriye handan Kalkan
SYSait Yeşillik
Sait Yeşillik
FDFevzi Demirel
Fevzi Demirel
ESEzgi Sönmez
Ezgi Sönmez
YBYasemin AKGUL BALABAN
Yasemin AKGUL BALABAN
ÖKÖzgür Kartal
Özgür Kartal
Chronic spontaneous urticaria (CSU) is a clinical condition that affects patients quality of life. Omalizumab is preferred in antihistamines resistant CSU cases. Urticaria activity score-7 (UAS-7) is a scale that shows the severity of the disease. The authors aimed to compare the long-term (60 months) efficacy and side effects of 150 mg and 300 mg doses of omalizumab in patients with CSU. 108 patients followed up at the clinic with the diagnosis of CSU were included. Omalizumab was started in patients who were resistant to conventional CSU treatment. Two groups were formed to receive 150 mg and 300 mg doses of omalizumab. Urticaria activity score (UAS-7), antihistamine usage, time to achieve disease-free stage, relapse after treatment, and side effects of omalizumab treatment were compared in the two groups. There were no statistically significant differences between the groups regarding basal characteristics and laboratory findings. Average follow-up time was sixty months. UAS-7 scores were similar in the follow-up. There were no adverse events in both groups. Retroactive design and single-center nature to reach a more significant number of patients. Lack of patients receiving the lowest dose 75 mg and the highest dose 600 mg of omalizumab. Absence of total body mass indexes of all patients. Besides, the use of distinct drugs may contribute to non confident results and is another limitation of this study. Since there is no significant difference between 150-300 mg omalizumab doses regarding long-term treatment efficacy and side effects in CSU patients, starting treatment with a 150 mg dose may be suitable. In patients who do not respond to 150 mg, the omalizumab dose can be increased to 300 mg. It will prevent unpredictable dose and time-dependent complications and will be a cost-effective approach even in strong economies.

29 August 2025 in Medicina
Verified
Journal Article
Open access
PDF file
OAOzge OZTURK AKTAS
Ozge OZTURK AKTAS
NÖNagihan Orhan Özer
Nagihan Orhan Özer
CEREN KAPLANKIRANCEREN KAPLANKIRAN
CEREN KAPLANKIRAN
BABegum Gorgulu Akin
Begum Gorgulu Akin
BÖBetül Özdel Öztürk
Betül Özdel Öztürk
ŞSŞadan Soyyiğit
Şadan Soyyiğit
Background and Objectives: Inborn errors of immunity are increasingly diagnosed in developing countries. Immunoglobulin replacement therapy (IGRT) remains the cornerstone of treatment in these patients, and its monitoring has gained importance for optimizing outcomes. We conducted a retrospective study to evaluate the relationship between IgG trough levels and infections in adults with inborn errors of immunity receiving IGRT. Materials and Methods: Adults diagnosed with primary immunodeficiency and receiving IGRT for at least six months were included. Serum IgG trough levels were measured, and infections during follow-up were systematically recorded. Results: A total of 31 adult patients (CVID: 29, XLA: 2) were analyzed. The mean follow-up was 13 months, with a mean serum IgG trough level of 815.8 ± 205.9 mg/dL, achieved with an average IGRT dose of 498.8 ± 93.0 mg/kg/month. Dose adjustments were made in 35.5% of patients, mostly due to weight changes and clinical indications. Overall, 74.2% of patients had at least one infection requiring antibiotics. Patients with mean IgG trough levels below 850 mg/dL had significantly higher rates of antibiotic-requiring infections (p = 0.032, Mann–Whitney U; mean difference = 0.109, 95% CI: 0.037–0.182; p = 0.005 via t-test). Multivariate regression confirmed that lower IgG trough levels were independently associated with higher antibiotic-requiring infection rates (B = −0.024, 95% CI: −0.045 to −0.002, p = 0.033), while IGRT dose and comorbidities were not significant. Conclusions: IGRT plays a key role in reducing antibiotic-requiring infections in patients with primary immunodeficiency. Regular monitoring and individualized dose adjustments may help optimize outcomes. Further prospective studies are needed to confirm these findings.

1 March 2026 in Allergologia et Immunopathologia
Verified
Journal Article
Open access
PDF file
FKFikriye handan Kalkan
Fikriye handan Kalkan
SYSait Yeşillik
Sait Yeşillik
FDFevzi Demirel
Fevzi Demirel
ASAli Selçuk
Ali Selçuk
MIMustafa İlKer İnAn
Mustafa İlKer İnAn
ÖKÖzgür Kartal
Özgür Kartal
Introduction: Common variable immunodeficiency (CVID) is a primary antibody deficiency characterized by hypogammaglobulinemia and recurrent infections. Studies on the effects of CVID in pregnant patients are still needed. We aimed to investigate the effects of CVID on pregnancy outcomes and newborns. Methods: We retrospectively evaluated 33 women with CVID and 94 pregnant women at our center. Patients were assessed based on infection rates, pregnancy complications, and use of immunoglobulin replacement therapy (IgRT) in both preterm and post-term periods. Patient data were collected from hospital databases and medical records. Results: The mean age at first pregnancy was 24.7 (17–45) years, with an average of 2.8 pregnancies per woman. CVID was detected before pregnancy in 24.2% of cases, and 24.2% of patients initiated IgRT during pregnancy. The live birth rate was 69.1%, while early fetal loss occurred in 27.7% of pregnancies, and stillbirth in 3.2%. Infection-related complications occurred in 18% of pregnancies and 14.9% of postpartum periods. The most common infections were upper respiratory and urinary tract infections. Parenteral antibiotic treatment was required for patients who did not receive IgRT during pregnancy. Neonatal infections were observed in 6.6% of cases, and the admission rate to the neonatal intensive care unit was 5.5%. Conclusion: Our study emphasizes that live birth and fetal loss rates in patients with CVID are comparable to those in the general population. Informing patients of the potential risks associated with consanguinity is crucial. Moreover, given the increased vulnerability of patients with CVID to infections, extra precautions are needed during pregnancy and the postpartum period.

1 January 2025 in Advances in Dermatology and Allergology
Verified
Journal Article
Open access
FDFevzi Demirel
Fevzi Demirel
FKFikriye handan Kalkan
Fikriye handan Kalkan
ASAli Selcuk
Ali Selcuk
SYSait Yesillik
Sait Yesillik
OKOzgur Kartal
Ozgur Kartal
Introduction Some diseases, including primary immunodeficiencies (PID), require treatment with intravenous immunoglobulin (IVIG). IVIG is an effective treatment and is generally well tolerated. IVIG can cause side effects ranging from mild reactions to, in rare cases, serious complications such...